Target intelligence / Profile preview

NADH:ubiquinone oxidoreductase complex assembly factor 8 (NDUFAF8)

Target
NDUFAF8
Molecular classification
Complex assembly factor, Protein-coding gene, Cx9C protein family member, Mitochondrial protein
01

Overview

NADH:ubiquinone oxidoreductase complex assembly factor 8 (NDUFAF8) is a small mitochondrial protein (74 amino acids) that plays an essential role in the *assembly of mitochondrial Complex I (NADH:ubiquinone oxidoreductase)*, a key enzyme in the oxidative phosphorylation (OXPHOS) system[1][2][3]. NDUFAF8 stabilizes the assembly factor NDUFAF5, ensuring proper Complex I biogenesis. Pathogenic bi-allelic mutations in NDUFAF8 disrupt this process, leading to severe mitochondrial disorders, most notably nuclear type mitochondrial complex I deficiency and Leigh syndrome, characterized by profound neurological impairments. NDUFAF8 belongs to the Cx9C protein family associated with mitochondrial function, and its deficiency presents as isolated Complex I deficiency in fibroblast and muscle cells, without affecting other mitochondrial complexes[1]. Currently, clinical interventions are limited to supportive care, with experimental gene repair strategies showing potential in cell models[1].

Other names
NDUFAF8C17orf89MC1DN34NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 8
02

Mechanism of action

Not applicable. No drugs directly targeting NDUFAF8 have defined mechanisms of action. Restoration of function has been observed in experimental systems using gene therapy or wild-type cDNA expression[1].

03

Biological functions

Assembly of mitochondrial Complex I (NADH:ubiquinone oxidoreductase)Stabilization of NDUFAF5 during Complex I assemblyRespiratory electron transport (indirectly, through its role in Complex I assembly)
04

Disease associations

Mitochondrial complex I deficiencyLeigh syndrome (a severe pediatric neurological disorder associated with mitochondrial dysfunction)Mitochondrial disease (in broader terms)
05

Safety considerations

Gene therapy safety: As with any gene therapy targeting mitochondrial function, consideration must be given to off-target effects, immune system activation, and potential for insertional mutagenesis
06

Interacting drugs

None currently known.
07

Biomarkers

Complex I deficiency in patient cells (e.g., fibroblasts) can be used as a functional biomarker for pathogenic variants in NDUFAF8Genetic mutations in NDUFAF8 (bi-allelic, pathogenic) serve as a diagnostic biomarker for a subset of Leigh syndrome cases

Beyond the preview

Go deeper on NADH:ubiquinone oxidoreductase complex assembly factor 8 (NDUFAF8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NADH:ubiquinone oxidoreductase complex assembly factor 8 (NDUFAF8).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call